Dementia - alzheimer. Alzheimer's disease with late onset
Conditions
Interventions
Intervention 1: Intervention group: Giving the extract (capsule) of saffron 15mg of the company's "green herbal products", twice a day. Intervention 2: Control group: Starch containing capsules twice
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Man and woman Patients older than 65 years (Late Onser Alzheimer Disease) Diagnosis of dementia based on DSM5 criteria and diagnosis of neurologist (confirmation with brain MRI and blood tests to exclude other causes) 3. Mild to moderate Alzheimer disease based on the MMSE cognitive test score between 11 and 24
Exclusion criteria
Exclusion criteria: Reversible dementias include delirium, pharmacotic agents, endocrine causes (hypothyroidism), metabolic causes, electrolyte, SOL, infections (encephalitis, syphilis, and AIDS) and atherosclerosis. irreversible cortical causes including fronto-temporal and lewy body dementia. irreversible subcortical causes include degenerative causes (such as corticobasal ganglia), inflammatory causes (such as lupus, vasculitis and multiple sclerosis) The cases that change the anti-inflammatory criteria of a person, such as fever, acute infectious diseases, vasculitis, antioxidant medications, anti-inflammatory drugs such as corticosteroids (such as asthma, rheumatoid arthritis, etc.) Patients with any other psychological or neurological disease based on DSM5 criteria. People with MMSE score higher than 24 (MCI) and below 11 (severe dementia) do not enter the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Memory scores in the mini mental state exam(MMSE) questionnaire. Timepoint: MMSE measurements at the beginning of the study (before the intervention) and 16 weeks after the intervention. Method of measurement: mini mental state exam.;Tumor necrosis factor alpha. Timepoint: The beginning of the study (before the intervention) and 16 weeks after the start of the intervention. Method of measurement: laboratory kits.;Interleukin 6. Timepoint: The beginning of the study (before the intervention) and 16 weeks after the start of the intervention. Method of measurement: Laboratory kits.;Interleukin 1 beta. Timepoint: The beginning of the study (before the intervention) and 16 weeks after the start of the intervention. Method of measurement: Laboratory kits.;Glutathione peroxidase. Timepoint: The beginning of the study (before the intervention) and 16 weeks after the start of the intervention. Method of measurement: Laboratory kits.;Superoxid dismutase. Timepoint: The beginning of the study (before the intervention) and 16 weeks after the start of the intervention. Method of measurement: Laboratory kit.;Total Antioxidan Capacity. Timepoint: The beginning of the study (before the intervention) and 16 weeks after the start of the intervention. Method of measurement: Laboratory kit.;Serum levels of malondialdehyde. Timepoint: The beginning of the study (before the intervention) and 16 weeks after the start of the intervention. Method of measurement: laboratory kits. | — |
Secondary
| Measure | Time frame |
|---|---|
| Memory level. Timepoint: The beginning of the study (before the intervention) and 16 weeks after the start of the intervention. Method of measurement: MMSE questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLeila Rasi marzabadi
Tabriz University of Medical Sciences
Outcome results
None listed